Editas Medicine, Inc. (EDIT) — SEC Financial Statements & Analysis

Editas Medicine, Inc. (EDIT) is a biological products, (no diagnostic substances) company, incorporated in DE. Editas Medicine, Inc. trades on Nasdaq as: EDIT. Editas Medicine, Inc. (EDIT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Editas Medicine, Inc. carries a market cap of $386.51M, a P/E ratio of -5.23x, a P/B ratio of 3.67x, a P/S ratio of 8.22x, an enterprise value of $257.77M, and an EV/EBITDA multiple of -3.51x. On profitability, it posts an operating margin of -161.39%, a net margin of -157.32%, a Return on Equity (ROE) of -118.82%, a Return on Assets (ROA) of -33.02%, and a Return on Invested Capital (ROIC) of -174.52%. Per share, it reports EPS of $-0.62, diluted EPS of $-0.62, free cash flow per share of $-1.01, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 20.83% year-over-year, net income growth of -68.78% year-over-year, and EPS growth of -77.91% year-over-year. On the balance sheet, it maintains a current ratio of 3.19x, a quick ratio of 3.13x, working capital of $149.63M, a debt-to-equity ratio of 1.25x, a debt ratio of 0.56, an interest coverage ratio of -15.18x, free cash flow of $-120.55M (TTM), and net debt of $-128.75M. Figures sourced from SEC EDGAR.

Market Cap

$386.51M

P/E TTM

-5.23x

EPS TTM

$-0.62

P/B TTM

3.67x

ROE TTM

-118.82%

ROA TTM

-33.02%

Debt To Equity

1.25x

Free Cash Flow TTM

$-120.55M

Net Revenue TTM Growth 1Y

20.83%

Data as of 2026-06-30 · Source: SEC EDGAR